Probes for Transient Kinase Complexes

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$98,917.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM090387-01
Agency Tracking Number:
GM090387
Solicitation Year:
2010
Solicitation Topic Code:
NIGMS
Solicitation Number:
PHS2010-2
Small Business Information
CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D, LOS ALAMOS, NM, 87544
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
147452275
Principal Investigator:
BENJAMIN WARNER
(505) 412-2345
WARNER@CALDERA-PHARMACEUTICALS.COM
Business Contact:
BENJAMIN WARNER
(505) 661-2420
court@cpsci.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK pathways play important roles in cellular differentiation and survival. MAPKs are serine/threonine protein kinases that can phoshorylate both cytoplasmic and nuclear targets. MAPKs are associated with aberrant, chronic or hyper-phosphorylation found in cancerous and other diseased tissues. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government